52 citations,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
14 citations,
November 2006 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
13 citations,
August 2013 in “Journal of pharmaceutical sciences” Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
9 citations,
January 2017 in “Farmacia” 1 citations,
November 2021 in “Société internationale d'urologie journal” Doctors should adjust how they treat men with prostate-related urinary problems during and after the COVID-19 pandemic.
December 2018 in “Actas urológicas españolas” 5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
728 citations,
August 1996 in “The New England Journal of Medicine” Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.
17 citations,
August 2011 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
5 citations,
April 2011 in “The Lancet” Untreated congenital adrenal hyperplasia can lead to complications like stroke and needs glucocorticoid treatment.
58 citations,
March 2006 in “Current topics in medicinal chemistry” Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
56 citations,
November 2007 in “Molecular and cellular endocrinology” Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
32 citations,
June 2019 in “Frontiers in Endocrinology” Polycystic Ovary Syndrome (PCOS) is common in women with conditions like anovulation, hirsutism, hair loss, and type 2 diabetes, and it can lead to health risks like heart disease, obesity, insulin resistance, and depression. Non-Classic Congenital Adrenal Hyperplasia (NC-CAH) is also discussed.
29 citations,
December 2012 in “Current Opinion in Endocrinology, Diabetes and Obesity” With careful management, people with congenital adrenal hyperplasia can have successful pregnancies and become parents.
21 citations,
February 2021 in “Frontiers in Endocrinology” Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.
7 citations,
October 2017 in “Urologic Oncology: Seminars and Original Investigations” Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.
6 citations,
January 2016 in “International Journal of Trichology” The conclusion is that more hair loss (androgenetic alopecia) is linked to larger prostate size, suggesting hair loss could be an early sign of benign prostatic hyperplasia.
4 citations,
April 2015 in “대한비뇨기종양학회지” For better medication adherence in benign prostatic hyperplasia treatment, tamsulosin and finasteride should be packaged together and taken at the same time.
1 citations,
January 2022 in “Food & Function” Certain Egyptian Sabal fruit extracts may help treat anti-androgenic diseases like benign prostatic hyperplasia.
October 2024 in “Journal of the Endocrine Society” Certain genetic variants reduce enzyme activity, contributing to non-classic congenital adrenal hyperplasia.
October 2024 in “Journal of the Endocrine Society” Certain genetic variants impair enzyme activity, contributing to non-classic congenital adrenal hyperplasia.
December 2023 in “Natural product research” Lignans from Urtica triangularis may help treat benign prostatic hyperplasia (BPH).
Men with depression and marijuana usage are more likely to be treated for lower urinary tract symptoms/benign prostatic hyperplasia.
December 2021 in “Daehanhanuihakoeji” The traditional herbal formulas Yongdamsagan-Tang and Paljung-san, along with the drug finasteride, can reduce inflammation and may work together without affecting each other's effectiveness against benign prostatic hyperplasia.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
April 2020 in “Journal of the Endocrine Society” Non-classic congenital adrenal hyperplasia (NCCAH) can mimic PCOS and requires genetic testing for proper diagnosis and treatment.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
A new mutation in the CYP11B1 gene was found in a woman with mild hyperandrogenemia, a rare cause of non-classic congenital adrenal hyperplasia.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
January 2018 in “Repositorio de Tesis - UNMSM” Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.
February 2019 in “Urology” Generic drugs for benign prostatic hyperplasia can cost up to 500% more at chain pharmacies compared to independent ones.